National Institute Of Allergy And Infectious Diseases (niaid)
Clinical trials sponsored by National Institute Of Allergy And Infectious Diseases (niaid), explained in plain language.
-
Scientists test new nasal spray vaccine for ebola
⭐️ VACCINE ⭐️ TerminatedThis study tested the safety and immune response of a new experimental Ebola vaccine given as a nasal spray. It involved 15 healthy adults who received two doses of either the vaccine or a placebo. The main goals were to check for side effects and see if the vaccine triggered an …
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 01, 2026 14:41 UTC
-
New hope for stubborn arthritis? drug combo trial seeks better control
Disease control TerminatedThis study tested whether adding a new drug called VIB4920 to standard arthritis medication (TNF inhibitors) could better control rheumatoid arthritis in adults whose current treatment wasn't working well enough. It was a Phase 2 trial that planned to enroll 104 participants but …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major mpox drug trial halted after failing to show benefit
Disease control TerminatedThis large study tested whether the antiviral drug tecovirimat could safely and effectively treat mpox. Over 700 participants with mpox were randomly assigned to receive either the drug or a placebo for 14 days. The trial was stopped early after an independent review board found …
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Halted trial tests new drug for mysterious Multi-Organ disease
Disease control TerminatedThis study tested whether adding the drug elotuzumab to standard steroid treatment (prednisone) could better control IgG4-Related Disease (IgG4-RD), a chronic condition that causes inflammation and scarring in various organs. It involved about 75 adults with active disease affect…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Immune drug tested to halt diabetes progression
Disease control TerminatedThis early-stage study tested different doses of an immune therapy called siplizumab in people recently diagnosed with type 1 diabetes. The main goal was to find a safe dose that changes certain immune cells, which might help protect the body's remaining insulin-producing cells. …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Targeted drug combo tested to tame lupus flares
Disease control TerminatedThis study aimed to see if two different drug combinations could better control active systemic lupus erythematosus (SLE) in specific groups of patients. It tested mycophenolate mofetil (MMF) alone or combined with voclosporin in adults with moderate to severe, non-organ-threaten…
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Zapping the vagus nerve: a new hope for kids with arthritis?
Disease control TerminatedThis study tested a device that delivers mild electrical pulses through the skin to stimulate a nerve in the ear, aiming to reduce pain and inflammation in children with juvenile idiopathic arthritis (JIA). Participants, aged 5-18, used the device at home daily for 8 weeks while …
Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC